{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:08:34Z","timestamp":1792267714298,"version":"4.4.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00044-026-03606-6","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:59:03Z","timestamp":1787025543000},"page":"1543-1547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Zidesamtinib (Jideytro\u00ae): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2257-0798","authenticated-orcid":false,"given":"Sumi","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-5652","authenticated-orcid":false,"given":"Longqin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"issue":"8","key":"3606_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","volume":"30","author":"K Bergethon","year":"2012","unstructured":"Bergethon K, Shaw AT, Ou S-HI, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers. J Clin Oncol. 2012;30(8):863\u201370. https:\/\/doi.org\/10.1200\/JCO.2011.35.6345.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3606_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","volume":"18","author":"A Drilon","year":"2021","unstructured":"Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. ROS1-dependent cancers \u2014 biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021;18(1):35\u201355. https:\/\/doi.org\/10.1038\/s41571-020-0408-9.","journal-title":"Nat Rev Clin Oncol"},{"issue":"25","key":"3606_CR3","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","volume":"368","author":"MM Awad","year":"2013","unstructured":"Awad MM, Katayama R, McTigue M, Liu W, Deng Y-L, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S, et al. Acquired Resistance to Crizotinib from a Mutation in CD74\u2013ROS1. N Engl J Med. 2013;368(25):2395\u2013401. https:\/\/doi.org\/10.1056\/NEJMoa1215530.","journal-title":"N Engl J Med"},{"issue":"2","key":"3606_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","volume":"21","author":"A Drilon","year":"2020","unstructured":"Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn M-J, Wolf J, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 2020;21(2):261\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(19)30690-4.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3606_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2302299","volume":"390","author":"A Drilon","year":"2024","unstructured":"Drilon A, Camidge DR, Lin JJ, Kim S-W, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, et al. Repotrectinib in ROS1 Fusion\u2013Positive Non\u2013Small-Cell Lung Cancer. N Engl J Med. 2024;390(2):118\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2302299.","journal-title":"N Engl J Med"},{"issue":"16","key":"3606_CR6","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1200\/JCO-25-00275","volume":"43","author":"M P\u00e9rol","year":"2025","unstructured":"P\u00e9rol M, Li W, Pennell NA, Liu G, Ohe Y, De Braud F, Nagasaka M, Felip E, Xiong A, Zhang Y, et al. Taletrectinib in ROS1\u2009+\u2009Non\u2013Small Cell Lung Cancer: TRUST. J Clin Oncol. 2025;43(16):1920\u20139. https:\/\/doi.org\/10.1200\/JCO-25-00275.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3606_CR7","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2159-8290.CD-22-0968","volume":"13","author":"A Drilon","year":"2023","unstructured":"Drilon A, Horan JC, Tangpeerachaikul A, Besse B, Ou S-HI, Gadgeel SM, Camidge DR, van der Wekken AJ, Nguyen-Phuong L, Acker A, et al. NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer Discov. 2023;13(3):598\u2013615. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0968.","journal-title":"Cancer Discov"},{"key":"3606_CR8","unstructured":"Food US, Administration D. FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer. Published July 22, 2026. Accessed July 28, 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer"},{"key":"3606_CR9","unstructured":"Horan JC, Tang X, Mente SR, Pelish HE, Shair MD, Tangpeerachaikul A. inventors; Nuvalent, Inc., assignee. Heteroaromatic macrocyclic ether chemotherapeutic agents patent US11542278. 2023."},{"issue":"7","key":"3606_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1158\/1535-7163.MCT-25-0025","volume":"24","author":"A Tangpeerachaikul","year":"2025","unstructured":"Tangpeerachaikul A, Mente S, Magrino J, Gu F, Horan JC, Pelish HE. Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations. Mol Cancer Ther. 2025;24(7):1005\u201319. https:\/\/doi.org\/10.1158\/1535-7163.MCT-25-0025.","journal-title":"Mol Cancer Ther"},{"key":"3606_CR11","unstructured":"Nuvalent I. JIDEYTRO (zidesamtinib) tablets, for oral use. Prescribing information. Revised July 2026. Accessed July 29, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/220185s000lbl.pdf"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03606-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03606-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03606-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:04:08Z","timestamp":1788343448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00044-026-03606-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3606"],"URL":"https:\/\/doi.org\/10.1007\/s00044-026-03606-6","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"29 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}